← Back to news

Markets

'Resumption of hostilities': Seized ship, vessel attacks push U.S.-Iran ceasefire toward brink

E

Millicom's Next Growth Is Built On Colombian Simplicity And Chilean Optionality

S

Taiwan Semi’s (TSM) Impressive Quarter Sets The Tone For 2026

Y

Here’s How Apple (AAPL) Plans to Compete with Meta (META) In Smart Glasses

Y

Amazon (AMZN) Price Target Lowered As CapEx Expected To Peak

Y

AbbVie (ABBV) Is One Of The Major Stock To Buy According To Wall Street

Y

Visa’s (V) Strong Moat To Bring Further Upside In The Stock

Y

Analysts Positive On Mastercard’s (MA) Future Prospects

Y

Meta (META) Gets Analyst Approval After Record App Downloads

Y

Adobe (ADBE) Is A Major Stock To Buy According To Analysts

Y

What Makes Microsoft (MSFT) The Best Stock To Buy At Wall Street?

Y

Nvidia (NVDA) Denies PC Business Takeover News as Foxconn Results Boost Stock

Y

Global cooperation on stablecoins critically important, BIS says

Y

Nike: Please Just Don't Do It

S

Huawei signs deal with Vietnamese bank SHB to expand Vietnam footprint

Y

lululemon Won't Remain Cheap For Too Long

S

India Gold Market Update: Mixed Reading

S

Direxion Heads in a New Direction With Income ETFs

Y

Why Clean Energy ETFs Have Wind in Their Sails

Y

US Automakers Poised to Benefit from Pentagon’s Request for Manufacturing Support

Y

Oil prices rise and US stocks give back a bit of their record-breaking rally

Y

Tesla Robotaxi Service Expands To Dallas And Houston

Y

Petrobras Expands Africa Push With São Tomé Block 3 Deal

Y

Xanadu (XNDU) Soars 237% This Week. Nvidia May Hold The Answer

Y

Maase (MAAS) Soars 84% as Firm Expands AI Foothold

Y

Avis Budget (CAR) Soars 65% — Here’s Why

Y

Revolution Medicines (RVMD) Jumps 54% on Stellar Drug Trial Results

Y

NextNav (NN) Up 49% as Firm Seen an Acquisition Target

Y

Hims & Hers (HIMS) Jumps 48% Ahead of Earnings

Y

Spyre (SYRE) Climbs 42% as Treatment Candidate Poses ‘Best-in-Class’ Potential

Y

National Australia Bank flags $503 million impairment hit on Mideast volatility

Y

Travere Therapeutics (TVTX) Climbs 40.8% on Filspari Approval

Y

Mizuho Cuts PT on ADMA Biologics Inc. (ADMA) to $24 From $30

Y

Wells Fargo Cuts PT on Nurix Therapeutics (NRIX) to $28 From $29

Y

JonesResearch Initiates Coverage of Relay Therapeutics (RLAY) With a Hold Rating

Y

Canaccord Initiates Coverage of Biohaven Ltd. (BHVN) With a Buy Rating

Y

H.C. Wainwright Initiates Coverage of Generate Biomedicines (GENB) With a Buy Rating

Y

Why Mesoblast Limited (MESO) is One of the Best Low Priced Biotech Stocks to Invest in

Y

Is Vir Biotechnology (VIR) One of the Best Low Priced Biotech Stocks to Invest In?

Y

Ocular Therapeutix (OCUL) Announces Additional Positive Data From the SOL-1 Phase 3 Superiority Trial of AXPAXLI

Y

Guggenheim Cuts PT on Valneva SE (VALN) to $11 From $13

Y

B. Riley Lifts PT on Theravance Biopharma (TBPH) to $17 From $14

Y

Cantor Fitzgerald Downgrades ADMA Biologics Inc. (ADMA) to Neutral From Overweight

Y

Is Halozyme Therapeutics (HALO) One of the Most Undervalued Biotech Stocks to Buy Right Now?

Y

RBC Capital Lifts PT on Incyte Corporation (INCY) to $95 From $92

Y

Why Royalty Pharma Plc (RPRX) is One of the Most Undervalued Biotech Stocks to Buy Right Now

Y

Raymond James Resumes Coverage of Jazz Pharmaceuticals (JAZZ) With an Outperform Rating

Y

Regeneron Pharmaceuticals (REGN) Announces Collaboration With Telix Pharmaceuticals Limited

Y

AMD: $600 Bullseye

S